Cota Healthcare, a data and technology platform for value-based precision medicine, today announced the signing of a major, multi-year collaboration with Novartis Pharmaceuticals Corporation to help improve clinical and cost outcomes for breast cancer patients.
As part of this agreement, which expands significantly on the previous announced collaboration entered into January 2016, teams from across Novartis Pharmaceuticals Corporation will leverage Cota's research-grade, real-world evidence, web-based analysis and visualization tools, and be supported by Cota's medical, data science, and technology experts. Utilizing the real-world evidence and technology platform supplied by Cota is expected to enable Novartis Pharmaceuticals Corporation to accelerate clinical development of new therapies for breast cancer and identify which patients will benefit most.
"Data and insight that comes directly from patient records - real-world evidence - is transforming how pharmaceutical and life science companies develop more precise, targeted therapies," said John Hervey, CEO of Cota. "Novartis has been an incredible collaborator over the last several years in adopting Cota's real-world evidence solutions to advance our shared goal of quantifiably improving and extending patient lives."
Cota's platform is powered by the patented Cota Nodal Address™ (CNA) system, a digital classification methodology that stratifies patients based on all the personal and clinical factors that matter to the individual. Each patient with the same CNA can be considered medically identical, and thus should have similar treatments and outcomes.
"We're excited about helping Novartis get deep insight into how patients are getting treatment in practice and connecting the dots all the way from patient to doctor to researcher," said Dr. Andrew Pecora, Founder & Executive Chairman of Cota. "Analyzing this data using CNAs is a critical factor in enabling healthcare companies to develop and target therapies that increase outcomes and lower the total cost of care."